Embarking on the journey of in vitro fertilization (IVF) involves many critical decisions, one of the most significant being the choice between fresh and frozen embryo transfer outcomes. Understanding the nuances of each approach is crucial for prospective parents and healthcare providers alike. This article delves into the evidence, offering a comprehensive overview of the advantages, disadvantages, and specific considerations for both fresh and frozen embryo transfers, based on recent research and clinical practice.

The Evolution of Embryo Transfer: From Multiples to Modern Practices

In the early days of IVF, predating effective embryo freezing techniques (the first live birth from frozen embryo transfer was in Australia in 1983), it was common practice to transfer multiple embryos after oocyte pick-up, with excess embryos often being discarded. This approach aimed to maximize the chances of pregnancy when freezing wasn't an option. However, transferring multiple embryos came with significant risks.

Risks Associated with Multiple Embryo Transfer

The practice of transferring multiple embryos, while sometimes increasing pregnancy rates, also led to higher rates of complications. Data from the HFEA in 2000, looking at thousands of cycles, showed that while transferring three embryos might slightly increase live birth rates compared to two, it significantly elevated the multiple birth rate. These multiple pregnancies (twins, triplets, etc.) are associated with several health risks:

Miscarriage
Preterm birth
Gestational Diabetes
Pregnancy-induced hypertension / Preeclampsia

Today, the standard practice in many regions is to transfer only one or two embryos in a fresh cycle. Remaining good-quality embryos are preserved for later frozen embryo transfer, often using advanced techniques like vitrification (fast freezing) over slow freezing.

Fresh vs. Frozen Embryo Transfer: A Core Comparison

The debate over whether frozen embryo transfer (FET) offers better outcomes than fresh transfer is a central point of discussion. One hypothesis suggests that the endometrium (the lining of the uterus) might be adversely affected by the high doses of gonadotrophins used in an IVF stimulation cycle, potentially leading to a less receptive environment for fresh embryo implantation. This has led to the 'freeze-all' strategy, where all viable embryos are frozen for transfer in a subsequent cycle.

Potential Advantages and Disadvantages of a Freeze-All Strategy

The freeze-all approach, followed by a frozen embryo transfer, presents several potential benefits and drawbacks:

Potential Advantages:

May avoid Ovarian Hyperstimulation Syndrome (OHSS)
Potentially better success rates in some patient groups

Disadvantages:

Delay in time to get pregnant
Increased costs
More steps in the process, potentially increasing chances of error

Evidence for PCOS Women (2016 Study)

A significant study in 2016 involved 1,508 women with Polycystic Ovary Syndrome (PCOS). It compared fresh embryo transfer to a freeze-all strategy followed by FET. The primary outcome measured was live birth after the first embryo transfer, predominantly involving Day 3 embryos, with most women receiving two embryos.

Outcomes for PCOS Women:

Live birth: Frozen 49.3% vs. Fresh 42%
Birth weight: Frozen 3.5 KG vs. Fresh 3.3 KG
Miscarriage: Frozen 22% vs. Fresh 32.7%

Other Outcomes:

OHSS: Frozen 1.3% vs. Fresh 7.1%
Preeclampsia: Frozen 4.4% vs. Fresh 1.4%
Multiple pregnancy: Frozen 15.7% vs. Fresh 14.2%

This study suggested a better success rate for freeze-all in PCOS women, along with a lower risk of OHSS and possibly higher birth weight.

Evidence for Ovulatory Women (2018 Study)

Another randomized controlled trial (RCT) in 2018 involved 2,157 average-aged 28-year-old ovulatory women, comparing fresh vs. freeze-all then FET. Around 90% of transfers involved Day 3 embryos, and about 90% transferred two embryos.

Outcomes for Ovulatory Women:

Live birth: Frozen 48.7% vs. Fresh 50.2% (no significant difference)
Multiple pregnancy: Frozen 17.5% vs. Fresh 16.2%
Birth weight (singleton): Frozen 3.3kg vs. Fresh 3.3kg
Birth weight (twin): Frozen 2.6kg vs. Fresh 2.6kg
Pregnancy loss (1st trimester): Frozen 7.8% vs. Fresh 6.8%
Pregnancy loss (2nd trimester): Frozen 1.5% vs. Fresh 4.7%
Preeclampsia: Frozen 4.4% vs. Fresh 3.3%
OHSS: Frozen 0.6% vs. Fresh 2.0%

For ovulatory women, this study indicated similar live birth rates between fresh and freeze-all strategies, with freeze-all potentially leading to slightly less OHSS.

Evidence for Non-PCOS Women (Multiple Studies)

Further research, including a 2018 study involving 782 non-PCOS women undergoing Day 3 transfer, and another study with 825 women, provided additional insights:

Outcomes (Non-PCOS, Day 3 transfer, n=782):

Live birth: Frozen 33.8% vs. Fresh 31.5%
Miscarriage: Frozen 6.4% vs. Fresh 3.8%
OHSS: Frozen 0.8% vs. Fresh 1.0%
Birth weight: Frozen 3.2kg vs. Fresh 3.0kg
Small for gestational age (SGA): Frozen 0.8% vs. Fresh 3.6%

Outcomes (n=825):

Live birth: Frozen 50% vs. Fresh 40%
Miscarriage: Frozen 23% vs. Fresh 25%
OHSS: Frozen 0.5% vs. Fresh 1.1%
Birth weight (singleton): Frozen 3.41kg vs. Fresh 3.29kg
Preeclampsia: Frozen 3.1% vs. Fresh 1.0%

Across these studies for non-PCOS women, there was no significant difference in ongoing pregnancy rate, live birth rate, or miscarriage rate. OHSS was also rare in both groups. However, some studies noted heavier babies and potentially a higher risk of preeclampsia with frozen transfers.

Overall Conclusions on Fresh vs. Freeze-All

Based on the evidence, the following conclusions can be drawn:

Freeze-all is suitable for women at high risk of OHSS.
There is likely a better success rate in PCOS women with a freeze-all strategy.
In normal ovulatory women, a freeze-all strategy generally shows similar success rates but may result in heavier babies and a longer time to pregnancy (TTP). There is a question mark regarding a potential increase in preeclampsia risk with frozen cycles for this group.

Optimizing Outcomes for Fresh Embryo Transfer

To achieve better pregnancy rates with fresh embryo transfer, two key factors are critical:

Adequate Progesterone Support: Granulosa cells, which produce progesterone, are removed during oocyte retrieval. This can lead to insufficient progesterone levels, vital for maintaining the uterine lining. Therefore, adequate luteal phase support with progesterone is essential. Progesterone can be administered via vaginal, intramuscular (IM), or subcutaneous (SC) routes.
Measure Progesterone Level on Trigger Day: If progesterone levels are high (> 1.5 ng/ml or 4.77 nmol/l) on the day of the trigger shot (which happens in 6-30% of patients), it is often recommended to freeze all embryos. High progesterone levels at this stage can negatively impact endometrial receptivity for a fresh transfer.

Routes of Progesterone Administration

Different routes for progesterone supplementation have their own pros and cons:

Intramuscular (IM): Often uses oil preparations, daily injections. It can be painful, cause local reactions, or allergic reactions. Popular in the USA, but improper administration can lead to sciatic nerve injury.
Subcutaneous (SC): Generally expensive but similar efficacy compared to vaginal progesterone.
Vaginal: Frequent administration might affect compliance. Can cause vaginal irritation, infection, or residue. Absorption can be variable.
Oral: Limited data available, and levels may not be easily measurable or effective for luteal support in IVF.

Optimizing Outcomes for Frozen Embryo Transfer (FET)

Achieving better outcomes with FET involves several considerations:

Method of Endometrial Preparation: This includes medicated (Hormone Replacement Therapy, HRT) cycles versus natural cycles.
Progesterone Support: Measuring progesterone levels before embryo transfer is crucial, with supplementation if levels are below a certain threshold.
Timing of FET: Whether to perform FET immediately following the OPU cycle or delay for one cycle. Retrospective studies have shown no significant difference in outcomes for immediate versus delayed transfer.

Endometrial Preparation: Medicated vs. Natural Cycle

Medicated (HRT) Cycle:

Involves exogenous estradiol to stimulate endometrial growth, followed by progesterone support.
May or may not include a GnRH agonist.
There is no corpus luteum (the temporary endocrine structure that produces progesterone naturally after ovulation), meaning the body is 100% reliant on exogenous estradiol and progesterone.
Transfer Day 3 embryos after 3 days of progesterone administration; transfer blastocysts after 5 days of progesterone administration.

Natural Cycle:

Relies on natural follicular growth to produce estradiol, stimulating the endometrium.
The corpus luteum, formed after natural ovulation, secretes progesterone.
Can be a pure natural cycle (waiting for spontaneous LH surge) or modified (with hCG trigger). There is no significant difference in outcomes between pure and modified natural cycles.

Comparing Outcomes: Medicated vs. Natural FET

While medicated and natural cycles often show similar pregnancy rates, other outcomes can differ significantly:

Hypertensive disorders, postpartum hemorrhage, and cesarean section were significantly higher after programmed (medicated) FET compared with natural cycle FETs.
A higher risk of birth weight > 4,500g was observed in the programmed FET group.
At least 10 publications have reported a higher risk of preeclampsia after programmed FET cycles.

Advantages of Medicated Cycle:

More predictable scheduling
Fewer ultrasound scans and blood tests
Suitable for women with irregular cycles

Advantages of Natural Cycle:

Less medication (reducing compliance issues)
Presence of endogenous progesterone production
Potentially better pregnancy outcomes with lower risks of complications as noted above.

A meta-analysis of 30 observational/cohort studies comparing natural cycle (NC) vs. medicated cycle (Med C) FET found that NC was associated with:

Higher Live Birth Rate (LBR)
Lower miscarriage rate
Lower preeclampsia
Lower preterm birth
Lower risk of pregnancy-induced hypertension (PIH)
Lower postpartum hemorrhage (PPH)
Lower Large for Gestational Age (LGA) babies

Progesterone Support in FET

In medicated cycles, if progesterone (P4) is below a certain threshold (e.g., 10 ng/mL) on the embryo transfer day, it is associated with a reduced success rate. Supplementing progesterone in women with low levels is therefore recommended. In natural cycles, the presence of the corpus luteum provides endogenous progesterone. Many clinicians, in their practice, measure progesterone levels on FET day and supplement with injected progesterone if levels are below 10 ng/mL.

Frequently Asked Questions (FAQ) about Embryo Transfer Outcomes

What is the main difference between fresh and frozen embryo transfer?

Fresh embryo transfer occurs in the same menstrual cycle as ovarian stimulation and egg retrieval, typically 3-5 days after retrieval. Frozen embryo transfer (FET) involves thawing an embryo that was cryopreserved from a previous IVF cycle and transferring it in a subsequent, separate menstrual cycle.

Is one type of embryo transfer always better than the other?

No, neither fresh nor frozen embryo transfer is universally superior. The optimal choice depends on individual patient factors, such as the risk of OHSS, the presence of PCOS, endometrial receptivity, and specific health considerations. For PCOS patients or those at high OHSS risk, a freeze-all strategy often yields better results.

How does progesterone affect embryo transfer outcomes?

Progesterone is crucial for preparing the uterine lining (endometrium) to be receptive to an embryo. In fresh cycles, insufficient natural progesterone due to egg retrieval may require supplementation. In FET cycles, adequate progesterone levels, whether naturally produced or supplemented, are vital for successful implantation. Monitoring progesterone levels and supplementing if low can significantly improve outcomes.

What are the risks associated with multiple embryo transfers?

Transferring multiple embryos significantly increases the risk of multiple pregnancies (twins, triplets), which carry higher risks of miscarriage, preterm birth, gestational diabetes, and preeclampsia for the mother and babies. Modern practice emphasizes single embryo transfer to minimize these risks.

Are there specific risks associated with medicated frozen embryo transfer cycles?

Medicated FET cycles, while offering predictable scheduling, have been associated with a potentially higher risk of hypertensive disorders in pregnancy, preeclampsia, postpartum hemorrhage, cesarean section, and babies born large for gestational age (LGA) compared to natural cycle FETs. These risks are still being investigated, but natural cycles appear to mitigate some of them.

Fresh and Frozen Embryo Transfer Outcomes